article thumbnail

Improving Patient-Physician Interaction with AI-Enhanced Data

PM360

However, maintaining meaningful interactions between patients and physicians has become increasingly challenging amid the complexities of clinical data management and modern medical practice demands, impacting patient satisfaction, trust, and healthcare outcomes. million by 2028.

article thumbnail

Immuno-oncology market set to grow in billions, but access concerns remain

Pharmaceutical Technology

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. According to the findings, 39% of surveyed high-prescribing physicians believe that the optimal place for immune-oncology agents is in a first-line setting.

Marketing 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. This allows for a large total eligible patient population despite capturing less patient share relative to other CD19 CAR-T agents.

article thumbnail

US Healthcare Industry Sectors: Facts, Trends, & Statistics

Medico Reach

trillion by 2028. The healthcare industry is currently undergoing a paradigm shift, and with a technology-enabled healthcare model in place, the role of general physicians will change forever. The industry was worth around 19.7% of the US GDP in 2020. The US national healthcare expenditure for 2020 was $4.1

article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

After this period, CMS will begin to include physician-administered drugs covered under Part B in the program. The IRA sets physician reimbursement of these products at the CMS-established MFP plus 6% versus current average sales price.

article thumbnail

Genetic Counselors Insight: Growing Popularity of At Home Testing

InCrowd

Based on their responses it seems that while these tests are growing in popularity with the market expected to surpass $10B in 2028 , Genetic Counselors reported concerns over patients using them as an indicator for health in addition to questions over the validity of the results patients receive. findageneticcounselor.nsgc.org.